Velkomstside
Hvad er
Restless Legs?
Danske artikler
Norske artikler
Eng. artikler 1
Eng. articles 2
Eng. articles 3
RLS og jernmangel
RLS hos børn
Dronningens gobelin m. m.
Video
Downloads
Debatforum
Min
Restless Legs
RLS-Foreningen
Links

Restless Legs-Patientforeningen
Hornbækvej 666 B
3100 Hornbæk

TELEFONTIDER
Hverdage efter 12:00

KONTAKT
Telefon 49 75 56 56
Fax 49 75 56 58
E-mail restless@legs.dk
Giro 100 3747









Anbefal artikel | Udskriv artikel



Study Demonstrates Mirapex®/ Sifrol® (pramipexole) Induces Rapid Relief from Restless Legs Syndrome

Study Presented at 56th Annual Meeting of the American Academy of Neurology

San Francisco 30 April 2004 – Results from a large-scale, randomized, double-blind study show Mirapex®/ Sifrol® (pramipexole) provides rapid relief in patients with restless legs syndrome (RLS). The results of the study were presented this week at the American Academy of Neurology (AAN) meeting in San Francisco, CA. RLS refers to “unpleasant, deep discomfort, including paresthesias, inside the calves when sitting or lying down, especially just before sleep, producing an irresistible urge to move the legs.”1

In an analysis of 109 patients randomized to either placebo (n=22) or Mirapex®/ Sifrol® at a daily dose of 0.125 mg (n=21), 0.25 mg (n=22), 0.5 mg (n=22), or 0.75 (n=22), Mirapex®/ Sifrol® showed efficacy over the dose range of 0.125 mg/day to 0.75 mg/day within 3 weeks of therapy. The primary endpoint of the study was the reduction in periodic limb movements during time in bed index (PLMI). Safety and tolerability of Mirapex®/ Sifrol® were favorable in all dose groups tested.

“These findings are most valuable in understanding which drugs are effective in treating RLS, a condition that up to 10% of the general population experiences,”2
said Dr. Markku Partinen, presenting author of the study results. “In this study, pramipexole demonstrates clearly that it is a promising new therapy for the treatment of restless legs syndrome.”

No medication is currently approved by the U.S. Food & Drug Administration for restless legs syndrome. Mirapex®/ Sifrol® is indicated for the treatment of the signs and symptoms of Parkinson’s disease. The most commonly reported adverse events in clinical trials of early and late Parkinson`s disease were dizziness, dyskinesia, extrapyramidal syndrome, hallucinations, headache, insomnia, somnolence, and nausea.

Boehringer Ingelheim and Pfizer co-promote Mirapex for Parkinson’s disease in the US.

Download PDF-file: 'Rapid Relief from RLS Symptoms with Pramipexole'.

Click here: http://restlesslegs.dk/download.asp

 Til top




____________________

References:
1. Dorland`s Illustrated Medical Dictionary, 30th edition, Philadelphia: Saunders, 2003.

2. Restless Legs Syndrome: A Clinical Study of 55 Patients. Claudio L. Bassetti; Doris Mauerhofer; Matthias Gugger; Johannes Mathis; Christian W. Hess. European Neurolog
____________________


Restless Legs-Portalen er tilegnet de mange, som er ramte af Restless Legs Syndrome